Back to results
US 2024/0200072 A1Published application
Allogeneic Cartilage Regeneration
AssigneeTarachon LLC
InventorTara SHARIF
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions and methods for treating and/or preventing arthritis, including osteoarthritis and/or rheumatoid arthritis in a patient.
Claims44
A method of treating, preventing, and/or controlling arthritis and the pain associated with arthritis in a patient, the method comprising:
- selecting a patient in need of treating, preventing, and/or controlling arthritis, torn or damaged meniscus cartilage, torn or damaged labrum, subchondral bone edema, torn or damaged joint ligament, torn or damaged patellar cartilage, or an external injury to the joint;
- administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising at least one of the following:
- (i) at least one miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof;
- (ii) at least one miRNA having a substitution, addition, and/or deletion of 1-5 bases to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect;
- (iii) at least one miRNA having 80% or more sequence identity to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect;
- (iv) a nucleic acid encoding at least one miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof;
- (v) a nucleic acid encoding at least one miRNA having a substitution, addition, and/or deletion of 1-5 bases to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect;
- (vi) a nucleic acid encoding at least one miRNA having 80% or more sequence identity to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect, or
- (vii) combinations thereof.
18 more elements
A pharmaceutical composition for treating, preventing, and/or controlling arthritis in a patient comprising at least one of the following:
- (i) at least one miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof;
- (ii) at least one miRNA having a substitution, addition, and/or deletion of 1-5 bases to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect;
- (iii) at least one miRNA having 80% or more sequence identity to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect;
- (iv) a nucleic acid encoding at least one miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof;
- (v) a nucleic acid encoding at least one miRNA having a substitution, addition, and/or deletion of 1-5 bases to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect;
- (vi) a nucleic acid encoding at least one miRNA having 80% or more sequence identity to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect, or
- (vii) combinations thereof.
16 more elements
A pharmaceutical composition comprising an exosome and an excipient, wherein the exosome comprises:
- (i) at least one miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof;
- (ii) at least one miRNA having a substitution, addition, and/or deletion of 1-5 bases to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect;
- (iii) at least one miRNA having 80% or more sequence identity to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect;
- (iv) a nucleic acid encoding at least one miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof;
- (v) a nucleic acid encoding at least one miRNA having a substitution, addition, and/or deletion of 1-5 bases to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect;
- or
- (vi) a nucleic acid encoding at least one miRNA having 80% or more sequence identity to a miRNA selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 38, and combinations thereof, and having a therapeutic effect.
16 more elements
A method of identification of signaling factors/biologic factors which can be used to induce cartilage growth in a patient in need thereof, the method comprising:
- Providing an older patient;
- isolating synovial fluid from the older patient;
- Isolating signaling factors from the synovial fluid, or cells or cell derivatives of synovial fluid, adipose tissue or bone marrow of adults, cells from embryo, fetuses, placentas, umbilical cord, Wharton Jelly or a mixture thereof, of the older patient;
- providing a younger patient;
- isolating synovial fluid from the younger patient,
- isolating signaling factors from the synovial fluid, or cells or cell derivatives of synovial fluid, adipose tissue or bone marrow of adults, cells from embryo, fetuses, placentas, umbilical cord, Wharton Jelly or a mixture thereof, of the younger patient;
- performing a comparison of the signaling factors isolated from the synovial fluid, or cells or cell derivatives of synovial fluid, adipose tissue or bone marrow of adults, cells from embryo, fetuses, placentas, umbilical cord, Wharton Jelly or a mixture thereof of the younger patient to the signaling factors isolated from the synovial fluid, or cells or cell derivatives of synovial fluid, adipose tissue or bone marrow of adults, cells from embryo, fetuses, placentas, umbilical cord, Wharton Jelly or a mixture thereof from the older patient;
- identifying the signaling factors which are unique to the synovial fluid, or cells or cell derivatives of synovial fluid, adipose tissue or bone marrow of adults, cells from embryo, fetuses, placentas, umbilical cord, Wharton Jelly or a mixture thereof of the younger patient;
- wherein the unique signaling factors from the younger patient are useful for growing cartilage.
6 more elements
Dependencies are inferred from the claim text.